Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.

Abstract

Since their introduction, statin (HMG-CoA reductase inhibitor) drugs have advanced the practice of cardiology to unparalleled levels. Even so, coronary heart disease (CHD) still remains the leading cause of death in developed countries, and is predicted to soon dominate the causes of global mortality and disability as well. The currently available non… (More)
DOI: 10.1007/s40265-015-0429-3

Topics

Cite this paper

@article{Kones2015CurrentTO, title={Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.}, author={Richard Kones and Umme Rumana}, journal={Drugs}, year={2015}, volume={75 11}, pages={1201-28} }